Center for Stem Cell Biology and Tissue Engineering, The Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, PR China.
Int J Biochem Cell Biol. 2013 Nov;45(11):2431-43. doi: 10.1016/j.biocel.2013.07.015. Epub 2013 Jul 30.
Although mesenchymal stromal cells (MSCs) have demonstrated great therapeutic potential, the heterogeneity of MSCs may be responsible for the incongruent data obtained in MSC-based preclinical studies and clinical trials. Here, four mouse clonal MSC lines, termed MSC1, MSC2, MSC3, and MSC4, were isolated and extensively characterized. MSC4 cells grew most rapidly and formed colonies of the largest size, whereas MSC3 cells exhibited the slowest growth and formed only a few tiny clusters. MSC4 cells could differentiate into adipocytes, osteoblasts, and chondrocytes in vitro, and more importantly, establish hematopoietic microenvironment in vivo; whereas the other lines displayed uni-adipogenic, osteo-chondrogenic, or non-differentiation potential. All lines were positive for Sca-1, CD106, and CD44; MSC4 was also positive for CD90.2. In terms of immunosuppressive capacity, MSC2, MSC3, and MSC4 cells exerted clear inhibitory effects on lymphocyte proliferation, whereas MSC1 did not. Further investigation revealed that the NO and not the PGE2 pathway may play a role in the different immunomodulatory effects of the cell lines. To clarify the molecular basis of this heterogeneity, we employed RNA sequencing to compare the gene expression profiles of the four subtypes, revealing a relationship between gene expression and variability in subtype function. This study provides novel information about the heterogeneity of MSCs and insight into the selection of optimal cell sources for therapeutic applications.
尽管间充质基质细胞(MSCs)具有巨大的治疗潜力,但 MSCs 的异质性可能是导致基于 MSC 的临床前研究和临床试验数据不一致的原因。在这里,我们分离并广泛表征了四个小鼠克隆 MSC 系,分别命名为 MSC1、MSC2、MSC3 和 MSC4。MSC4 细胞生长最快,形成的集落最大;而 MSC3 细胞生长最慢,仅形成少数微小的簇。MSC4 细胞可以在体外分化为脂肪细胞、成骨细胞和成软骨细胞,更重要的是,在体内可以建立造血微环境;而其他系则表现出单一的成脂、成骨-软骨或非分化潜能。所有系均表达 Sca-1、CD106 和 CD44;MSC4 还表达 CD90.2。在免疫抑制能力方面,MSC2、MSC3 和 MSC4 细胞对淋巴细胞增殖有明显的抑制作用,而 MSC1 则没有。进一步的研究表明,NO 而不是 PGE2 途径可能在细胞系的不同免疫调节作用中发挥作用。为了阐明这种异质性的分子基础,我们采用 RNA 测序比较了四个亚型的基因表达谱,揭示了基因表达与亚型功能变异性之间的关系。这项研究提供了关于 MSCs 异质性的新信息,并深入了解了治疗应用中最佳细胞来源的选择。